Drugs / Astragalus
Astragalus
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 28 trials · 1 met primary | ||||||
| Phase 2 | NCT05647473 | Feb 2024 → May 2025 | Alzheimer disease, orthostatic hypotension | Fujian Medical University Union Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT06234072 | Feb 2024 → Jan 2027 expected | malignant exocrine pancreas neoplasm | Shenzhen University General Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05506891 | Oct 2023 → Jul 2024 | parkinsonian disorder | Fujian Medical University Union Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT06694597 | May 2023 → Mar 2024 | Alzheimer disease | Fujian Medical University Union Hospital | Completed | No outcome recorded |
| Phase 2 | NCT02795390 | Nov 2016 → Aug 2018 | constipation disorder | Hong Kong Baptist University | Completed | Met primary |
| Phase 2 | NCT03911921 | Jun 2015 → Feb 2019 | cancer-related condition | Peking University Cancer Hospital & Institute | Completed | No outcome recorded |
| Phase 2 | NCT01939236 | May 2010 → Aug 2012 | heart failure | Beijing University of Chinese Medicine | Completed | No outcome recorded |
| Phase 2 | NCT01428401 | Jan 2008 → Dec 2010 | stroke disorder | China Medical University Hospital | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03271697 | Sep 2017 → Sep 2020 | acquired aneurysmal subarachnoid hemorrhage | China Medical University Hospital | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01554787 | Jan 2012 → Dec 2013 | stroke disorder | China Medical University Hospital | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02846207 | Mar 2016 → Dec 2019 | cerebral infarction | Dongfang Hospital Beijing University of Chinese Medicine | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT01847807 Comparator | Jan 2011 → Jun 2015 | metabolic syndrome X | LanZhou University | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Astragalus | “Astragalus 60g. Oral administration, twice one day, for 12weeks.” NCT02846207 ↗ |
| Known as | Astragalus membranaceus | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03911921 ↗ |
| Known as | Astragalus Membranaceus Root | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06694597 ↗ |
| Known as | Huang-Chi | “Astragalus membranaceus (AM, Huang-Chi) is a Chinese herb used extensively in China as a traditional treatment to treat stroke for a long time, and a number of studies have...” NCT03271697 ↗ |
| Known as | HuangQi | “MaZiRenWan 10g plus HuangQi 20g are chosen as the core prescription.” NCT02795390 ↗1“Qi deficiency：huangqi, dangshen” NCT01939236 ↗ |
| Action | Inhibit | “Investigators found that Astragalus can not only inhibit the growth of pancreatic tumors” NCT06234072 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “Chinese Herb Astragalus membranaceus” NCT01428401 ↗ |
| Route | Oral | “drunk with warm water” NCT05506891 ↗ |